Respiratory viral and bacterial infections are common in people with idiopathic pulmonary fibrosis (IPF) and might play a role in the development of the disease, a study reported. The study, “The role of viral and bacterial infections in the pathogenesis of IPF: a systematic review and…
News
People should be reimbursed for costs of using Ofev (nintedanib) to treat progressive fibrosing interstitial lung diseases (PF-ILD), two agencies that help to guide health policy in Canada — the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux…
The first lung transplant using LUNGguard, a cold storage device for transporting donor lungs, was performed in a person with idiopathic pulmonary fibrosis (IPF), Paragonix Technologies, the device’s developer, announced. The first device of its kind to be cleared by the FDA, it became commercially available…
Cynata Therapeutics will begin a preclinical study to investigate the mechanisms underlying the high potency of its cell therapy, Cymerus mesenchymal stem cells (MSCs), in treating lung diseases such as idiopathic pulmonary fibrosis (IPF). In an earlier study, the investigational therapy was able…
Insilico Medicine announced that it has found a new therapeutic target and potential therapy candidate for idiopathic pulmonary fibrosis (IPF) using artificial intelligence (AI), a company specialty. The potential therapy, a small molecule inhibitor, has been validated in preclinical…
MYMD-1, MyMD Pharmaceuticals’ lead candidate for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting the root causes of inflammation in idiopathic pulmonary fibrosis (IPF), according to data from a recent study. The therapy reduced the activity of molecules that are known drivers of…
For Rare Disease Day this Feb. 28, the Pulmonary Fibrosis Foundation (PFF) wants to raise public awareness of pulmonary fibrosis (PF), its symptoms and the importance of an early diagnosis. “The PFF is committed to providing quality disease education for the PF community,” Joyce S. Lee, senior medical advisor for…
Diagnosed with sickle cell disease as a 6-month-old, Tristan Lee has faced a lot of challenges over his 37 years of life. But from a young age, he also learned how to turn those trials into triumphs. At age 9, a stroke due to his disease left him paralyzed…
Pretreatment with retinoic acid was found to stimulate the repair of damaged alveoli — the tiny air sacs in the lungs — in a mouse model of idiopathic pulmonary fibrosis (IPF) by upregulating a molecule called PDGFA. The researchers used an aged mouse model to simulate the lung…
A DNA sensor protein called STING was found to play an unexpected protective role in fibrosis development by regulating inflammatory immune responses in an induced idiopathic pulmonary fibrosis (IPF) mouse model, a study has discovered. The study, “…
Your PF Community
Recent Posts
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
- On my diagnosis journey, I felt like I was moving in slow motion January 6, 2026
- Amid a sea of data, the PF community is critical in the search for a cure December 23, 2025
- FDA approves Jascayd for adults with progressive pulmonary fibrosis December 23, 2025
- Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data December 17, 2025
